Background

Sarcomas are uncommon cancers that can affect any part of the body. There are many different types of sarcoma and subtypes can be grouped into soft tissue or bone sarcomas. About 15 people are diagnosed every day in the UK. 3 in every 200 people with cancer in the UK have sarcoma.

A highly granular dataset with a confirmed sarcoma event including hospital presentation, serial physiology, demography, treatment prescribed and administered, prescribed and administered drugs. The infographic includes data from 27/12/2004 to 31/12/2021 but data is available from the past 10 years+.

PIONEER geography: The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix.

EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Scope: All hospitalised patients from 2004 onwards, curated to focus on Sarcoma. Longitudinal & individually linked, so that the preceding & subsequent health journey can be mapped & healthcare utilisation prior to & after admission understood. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (timings, staff grades, specialty review, wards and triage). Along with presenting complaints, outpatients admissions, microbiology results, referrals, procedures, therapies, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations and others), and all blood results (urea, albumin, platelets, white blood cells and others). Includes all prescribed & administered treatments and all outcomes. Linked images are also available (radiographs, CT scans, MRI).

Available supplementary data: Matched controls; ambulance, OMOP data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

Snapshot img

Multi-Cancer Early Detection Market Size 2025-2029

The multi-cancer early detection market size is forecast to increase by USD 1.29 billion at a CAGR of 15.4% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of cancer and the focus on developing innovative diagnostic tools. Next-generation sequencing technologies are revolutionizing the identification of cancer-related biomarkers, including DNA, RNA, and proteins, enabling the detection of genetic mutations at an early stage. However, limited insurance coverage poses a challenge to market growth. To address this, data analytics plays a crucial role in improving diagnostic accuracy and reducing healthcare costs. Biomarkers, whether DNA-based or protein-based, are essential for the early detection of various types of cancer. The market is expected to continue its expansion as advancements in technology and research lead to more accurate and cost-effective diagnostic solutions.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market is witnessing significant growth due to the increasing prevalence of cancer and the need for effective screening methods. Early detection of cancer can lead to improved patient survival rates and reduced mortality. Several technological advancements are driving the market. These include the use of nanotechnology for enhancing the sensitivity and specificity of diagnostic tools, big data analytics for identifying cancer-related biomarkers, and machine learning algorithms for analyzing genomic and proteomic data. Next-generation sequencing technologies, such as genome sequencing and RNA sequencing, are playing a crucial role in the discovery of genetic mutations associated with various types of cancer.
Liquid biopsies, which involve the analysis of DNA, RNA, and proteins present in bodily fluids, are gaining popularity as non-invasive screening methods for early cancer detection. Molecular signatures derived from genomic, proteomic, and biomarker data are being used to develop diagnostic tools for multi-cancer screening. These tools offer the potential for personalized treatment plans based on an individual's unique genetic profile. The integration of data from various sources, including electronic health records and wearable devices, is facilitating the development of more accurate and comprehensive diagnostic tools. This data can be analyzed using advanced data analytics techniques to identify patterns and trends that may indicate the presence of cancer.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Gene panel
  LDT
  Liquid biopsy
  Others


End-user

  Hospitals
  Diagnostic laboratories
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy
    Spain


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The gene panel segment is estimated to witness significant growth during the forecast period.

In the realm of preventive healthcare, biotechnology firms are making significant strides in the market through breakthrough device designs. Gene panel testing is a vital segment of this industry, focusing on the analysis of specific genes to identify mutations linked to various cancer types. These panels play a crucial role in personalized cancer screening and prevention by targeting inherited gene alterations. Predictive genetic testing is a key application of gene panel testing. This testing assesses inherited mutations in individuals with a family history of cancer, such as BRCA1 and BRCA2 gene mutations, which increase the risk of breast, ovarian, and other cancers.

Similarly, Lynch syndrome testing identifies mutations in mismatch repair (MMR) genes, linked to colorectal and endometrial cancers. Biotechnology companies securing venture capital investments and collaborating with national screening programs are advancing precision medicine in cancer screening. This approach tailors treatment plans based on an individual's unique genetic makeup, enhancing overall patient care. Genome science is at the forefront of these advancements, offering a more targeted and effective approach to cancer prevention and early detection. In the US market, insurance coverage for gene panel testing is expanding, making these tests more accessible to a broader population. This trend is expected to fuel the growth of the market in the coming years.

Get a glance at the market report of share of various segments Request Free Sample

The Gene panel segment was valued at USD 232.70 million in 2019 and showed a gradual increase during the foreca

Snapshot img

Breast Cancer Therapeutics Market Size 2024-2028

The breast cancer therapeutics market size is forecast to increase by USD 15.64 bn at a CAGR of 8.4% between 2023 and 2028.

The market is experiencing significant growth due to the rising prevalence of breast cancer and the emergence of novel therapeutics. Hormone therapy and radiation therapy continue to be popular treatment options, while oncology drugs such as monoclonal antibodies, biosimilars, and vaccines are gaining popularity. Artificial intelligence is revolutionizing cancer diagnostics and treatment plans, enabling early detection and personalized treatment. Online pharmacies and telemedicine are making treatments more accessible, especially in remote areas. The high cost of treatment remains a challenge, but education and nutrition programs are helping to mitigate this issue. Protein-based therapies, gelatin, and tablets are also key components of breast cancer therapeutics.In the US, the market is expected to grow steadily due to increasing awareness and advancements in technology and treatment methods.

What will be the Size of the Breast Cancer Therapeutics Market During the Forecast Period?

Request Free SampleThe market encompasses a range of treatments designed to combat this prevalent form of cancer among females. Key therapeutic approaches include chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Oncology drugs and therapeutics play a pivotal role in addressing breast cancer, targeting various proteins and cells, such as milk ducts, milk-producing lobules, and tumors. Breast cancer awareness initiatives and screening programs are instrumental in early detection, leading to improved patient outcomes. Artificial intelligence and advanced diagnostics are increasingly utilized to enhance the accuracy of diagnoses, enabling more effective interventions. Breast cancer can manifest as lumps, red patches, pain, swelling, or symptoms affecting the nipple, bones, breathing, or lymph nodes.Surgical tumor removal and medications, including hormonal therapies, are essential components of treatment plans. Despite advancements, breast cancer continues to pose significant health challenges, with ongoing research and innovation required to address the complexities of this disease.

How is this Breast Cancer Therapeutics Industry segmented and which is the largest segment?

The breast cancer therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Disease TypeInvasive breast cancersDuctal carcinoma in situTherapyTargeted therapyHormonal therapyChemotherapyGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Disease Type Insights

The invasive breast cancers segment is estimated to witness significant growth during the forecast period. Invasive ductal carcinoma, also known as infiltrating ductal carcinoma, is the most prevalent type of breast cancer, accounting for approximately 80% of diagnoses. This form of cancer arises when cancerous cells invade the fibrous or fatty tissue of the breast beyond the milk ducts. Symptoms include breast swelling, skin irritation, pain, nipple discomfort, redness, and nipple discharge, among others. Risk factors include genetics, hormonal imbalances, obesity, alcohol intake, and prior radiation therapy. Hormonal therapies, such as tamoxifen and aromatase inhibitors, chemotherapy, radiation therapy, targeted therapies, including Herceptin for HER2-positive tumors, and immunotherapies are common treatments. Early detection through breast cancer awareness campaigns, screening programs, and regular self-examinations contribute to improved survival probabilities and reduced morbidity.The development of oncology drugs and therapeutics, including proteins and biosimilars, continues to advance treatment options. Government support, hospital visits, and recovery rates are crucial aspects of breast cancer care. Hormonal therapy, obesity, and family history are significant factors in cancer type analysis. Hospital pharmacies and online pharmacies provide access to medications.

Get a glance at the market report of various segments Request Free Sample

The Invasive breast cancers segment was valued at USD 22.55 bn in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American the market is experiencing significant growth due to the availability of r

Lung cancer is one of the leading causes of cancer-related deaths worldwide. To reduce the mortality rate, early detection and proper treatment should be ensured. Computer-aided diagnosis methods analyze different modalities of medical images to increase diagnostic precision. In this paper, we propose an ensemble model, called the Mitscherlich function-based Ensemble Network (MENet), which combines the prediction probabilities obtained from three deep learning models, namely Xception, InceptionResNetV2, and MobileNetV2, to improve the accuracy of a lung cancer prediction model. The ensemble approach is based on the Mitscherlich function, which produces a fuzzy rank to combine the outputs of the said base classifiers. The proposed method is trained and tested on the two publicly available lung cancer datasets, namely Iraq-Oncology Teaching Hospital/National Center for Cancer Diseases (IQ-OTH/NCCD) and LIDC-IDRI, both of these are computed tomography (CT) scan datasets. The obtained results in terms of some standard metrics show that the proposed method performs better than state-of-the-art methods. The codes for the proposed work are available at https://github.com/SuryaMajumder/MENet.

Snapshot img

Brain Tumor Diagnostics Market Size 2024-2028

The brain tumor diagnostics market size is forecast to increase by USD 152.9 million at a CAGR of 3.4% between 2023 and 2028.

Brain tumor diagnostics is a critical area of medical research and healthcare, with a significant focus on improving patient outcomes for those diagnosed with gliomas and other types of brain cancers. The market for brain tumor diagnostics is experiencing notable growth due to several factors, including the increasing prevalence of brain cancer, advancements in diagnostic procedures, and ongoing research and development in this field. However, challenges persist, such as unfavorable reimbursement scenarios and the need for more effective treatment modalities like chemotherapy and radiotherapy to improve patient survival rates. Hospitals and diagnostic centers are crucial in providing accurate and timely diagnoses, ensuring that patients receive the best possible care. As the demand for advanced diagnostic tools and techniques continues to grow, it is essential to address these challenges and work towards improving patient outcomes and advancing the field of brain tumor diagnostics.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market represents a significant area of growth in the healthcare industry, driven by the increasing prevalence of neurological disorders, including brain cancer. According to the American Brain Tumor Association, an estimated 80,000 Americans are diagnosed with a primary brain tumor each year. Early detection and accurate diagnosis of brain tumors, such as malignant glioblastoma, are crucial for improving patient survival rates and effective treatment. Advanced diagnostic solutions are increasingly being adopted for brain tumor diagnostics. These solutions include non-invasive techniques, such as magnetic resonance imaging (MRI), which provides detailed images of the brain and can help identify tumors. Imaging investigations, such as MRIs, play a vital role in diagnosing brain tumors, allowing medical professionals to assess the size, location, and extent of the tumor. Screening programs are also being implemented to increase the early detection of brain tumors. These programs often involve a combination of diagnostic procedures, including neurological evaluations, blood tests, genetic testing, and biopsies. 



Brain tumors, including malignant glioblastoma, can be challenging to diagnose due to their non-specific symptoms and the difficulty of accessing brain tissue for biopsy. However, advancements in diagnostic tools and techniques are helping to improve the accuracy and speed of brain tumor diagnoses. These advancements include the development of more sensitive imaging technologies and the integration of artificial intelligence and machine learning algorithms into diagnostic procedures. In conclusion, the market is a critical area of growth in the healthcare industry, driven by the increasing prevalence of neurological disorders and the need for accurate and early diagnosis of brain tumors. Advanced diagnostic solutions, such as non-invasive imaging technologies and screening programs, are playing an increasingly important role in the detection and identification of brain tumors. Effective treatment regimens, including chemotherapy and radiotherapy, rely on accurate and timely diagnoses, making the continued advancement of brain tumor diagnostics a priority for improving patient outcomes.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Imaging test
  Biopsy
  Molecular testing
  Others


Geography

  North America

    Canada
    Mexico
    US


  Europe

    Germany
    UK
    France


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The imaging test segment is estimated to witness significant growth during the forecast period.

Brain tumors are a significant health concern, and timely and accurate diagnosis is crucial for effective treatment. Medical tools play a vital role in the diagnosis of brain tumors, with various methods being employed. Imaging investigations, such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans, are commonly used to identify tumors. Biopsies, which involve extracting tissue samples from the tumor for further examination, are also essential for determining the type and severity of the tumor.

Furthermore, blood tests and genetic testing are other diagnostic methods that are gaining popularity. Neurological evaluations, which assess the function of the nervous system, are also used to diagnose brain tumors. The choice of diagnostic method depe

Snapshot img

Teleradiology Market Size 2024-2028

The teleradiology market size is forecast to increase by USD 3.83 billion at a CAGR of 17.55% between 2023 and 2028.

The increasing prevalence of diseases, coupled with the growing geriatric population, is the key driver of the teleradiology market. Aster Medical Imaging LLC is a key company in this space, offering teleradiology services such as urgent after-hours consultations with radiologists, urgent daytime support for emergency cases, routine overflow, and backlog management. The company's services help healthcare providers efficiently manage radiology needs, improving patient care and addressing the rising demand for timely diagnostic solutions.
Technological advancements and upgrades in teleradiology modalities enable radiologists to provide accurate diagnoses from a distance, improving accessibility and efficiency in healthcare delivery and mhealth solutions. Furthermore, government initiatives encouraging the adoption of healthcare IT have created a favorable regulatory environment for teleradiology services. These factors collectively contribute to the expansion of the teleradiology market, offering opportunities for growth and innovation in the healthcare industry.

What will be the Size of the Teleradiology Market During the Forecast Period?

Request Free Sample

The market is experiencing significant growth due to the integration of Artificial intelligence (AI) in healthcare, particularly In the interpretation of medical imaging for various conditions. Preliminary and final reports are shared between healthcare professionals and Neuroradiologists through XERO Exchange Network and other teleradiology platforms. The geriatric population, with target diseases such as cardiovascular conditions, cancer, and osteoarthritis (OA), significantly benefits from timely interventions based on accurate and efficient diagnostic data.
However, higher-resolution imaging and 3D imaging are essential for diagnosis and treatment planning In the elderly population. AI enhances image interpretation, ensuring diagnostic accuracy and improving the overall quality of healthcare. The market is driven by the increasing demand for cutting-edge imaging solutions to manage musculoskeletal ailments like OA. The Osteoarthritis Action Alliance focuses on the importance of early diagnosis and intervention for improved patient outcomes.

How is this Teleradiology Industry segmented and which is the largest segment?

The teleradiology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Modality

  CT
  X-ray
  Ultrasound
  MRI
  Nuclear imaging


Component

  Hardware
  Software
  Telecom and networking


End Use

  Hospital
  Radiology Clinics
  Ambulatory Imaging Center


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Modality Insights

The CT segment is estimated to witness significant growth during the forecast period. In the dynamic and evolving teleradiology industry, healthcare professionals leverage advanced imaging systems to deliver accurate and timely diagnostic reports remotely. Artificial Intelligence (AI) is increasingly being integrated into medical imaging to enhance preliminary reports, ensuring that final reports are more precise and efficient. Hospitals and neuroradiologists rely on various modalities of CT scanners for diagnosing target diseases such as cardiovascular conditions, cancer, and osteoarthritis (OA) In the elderly population. Agfa Healthcare's XERO Exchange Network plays a crucial role in facilitating the secure exchange of diagnostic data between healthcare providers, enabling timely interventions and improving the quality of healthcare. Multi-detector CT (MDCT) scanners, with their ability to acquire images more quickly and with greater resolution, are a significant modality In the teleradiology industry. These scanners are essential for interpreting complex medical images, particularly In the context of cardiovascular conditions and cancer. The integration of AI in image interpretation further enhances the diagnostic capabilities of these systems, ensuring accuracy and efficiency In the diagnostic processes.

Moreover, the teleradiology industry is witnessing a shift towards streamlining workflows and cost-cutting measures during economic recessions. Broadband networks and data security are critical considerations in ensuring connectivity and data privacy. Security protocols are essential to mitigate potential connectivity issues and maintain the confidentiality of diagnostic data. The integration of AI in teleradiology platforms and services is expected to revolutionize the industry, providing 3D imaging c